

■ 11:15 - 13:00 HALL T1		
Proffered Papers Session: Melanoma and Skin Cancer		
<i>Chair: A.M.M. Eggermont (France)</i>		
<i>Chair: R. Marais (United Kingdom)</i>		
11:15	Dramatic Efficacy of Neoadjuvant Therapy by the Association Cisplatin, Fluorouracil and Cetuximab in Locally Advanced Non Resectable Epidermoid Skin Carcinoma	9.300
<i>C. Mateus, F. Kolb, F. Janot, P. Duviillard, G. Mamelle, C. Robert</i>		
11:30	Ultrasound (US) Guided Fine Needle Aspiration Cytology (FNAC) Predicts Sentinel Node (SN) Metastases and Improves the Nomogram for Melanoma Patients	9.301
<i>C. Voit, A.J.C. van Akkooi, P. Siegel, G. Schaefer-Hesterberg, W. Sterry, A. Schoengen, A.M.M. Eggermont</i>		
11:45	Prognostic Significance of the Size, Site and Penetrative Depth of Sentinel Node Metastases in Melanoma Patients - an International Multicenter Study	9.302
<i>S. van der Ploeg, A.C.J. van Akkooi, P. Rutkowski, M. Cook, C.R. Rossi, O.E. Nieweg, P.A.M. van Leeuwen, C. Voit, C. Verhoef, A.M.M. Eggermont</i>		
12:00	131I Targeted Radionuclide Therapy by Melanin Linked Molecules for Melanoma Treatment	9.303
<i>F. Degoul, S. Besse, J. Jacquemot, J. Papon, F. Mischellany, A. Cayre, J. Cluzel, J.M. Chezal, N. Moins, M. Bonnet</i>		
12:15	Percutaneous Hepatic Perfusion (PHP) Vs. Best Alternative Care (BAC) for Patients (pts) With Melanoma Liver Metastases - Efficacy Update of the Phase 3 Trial (NCT00324727)	9.304
<i>J.F. Pingpank, M. Hughes, H.R. Alexander, M. Faries, J. Zager, G. Siskin, S. Agarwala, E. Whitman, C. Nutting, O.S. Ozkan</i>		
12:30	A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial	9.305
<i>A.M. Di Giacomo, P.A. Ascierto, E. Pittiglio, P. Queirolo, L. Pilla, R. Ridolfi, M. Santinami, A. Testori, G. Parmiani, M. Maio</i>		
12:45	Safety and Efficacy of Ipilimumab-treated Patients With Melanoma and Brain Metastases	9.306
<i>K. Margolin, F.S. Hadi, D.F. McDermott, D.P. Lawrence, O. Hamid, I. Puzanov, J.A. Thompson, M.S. Ernstoff, T.L. Michener, K.N. Heller</i>		

■ 11:15 - 13:15 HALL T2		
Advocacy and Ethics Session: Getting Personal - Treatment in the Age of Targeted Therapies		
Introduction		
<i>Co-Chair: S. Kyriakides (Cyprus)</i>		
<i>Co-Chair: F. Cardoso (Portugal)</i>		
11:15	Personalised Medicine - Would it Work for Me?	
<i>Speaker: R. Wilson (United Kingdom)</i>		
11:40	Questions and Answers	
11:45	Challenges on the Road to Drug Approval	
<i>Speaker: F. Pignatti (United Kingdom)</i>		
12:00	Questions and Answers	
12:05	Targeted Therapies - At What Cost?	
<i>Speaker: F.B. Kristensen (Denmark)</i>		
12:20	Questions and Answers	
12:25	Personalised Medicine - Can Industry Deliver?	
<i>Speaker: G. Gudi (Italy)</i>		
12:40	Concluding Remarks & Discussion	

■ 11:15 - 13:15 HALL A5		
Scientific Symposium: Molecular Imaging of Hypoxia		
<i>Chair: R. Blasberg (USA)</i>		
<i>Chair: E. Lartigau (France)</i>		
Introduction		
<i>Speaker: R. Blasberg (USA)</i>		
11:15	Imaging of Hypoxia With PET Radiotracers, Including, Ca-IX Antibodies	16
<i>Speaker: H. Schöder (USA)</i>		
11:25	Imaging of Hypoxia With PET Radiotracers, Including, Ca-IX Antibodies	16
<i>Speaker: H. Schöder (USA)</i>		
11:50	Interest of Functional Imaging to Guide Stereotactic Radiotherapy	17
<i>Speaker: E. Lartigau (France)</i>		
12:15	Imaging of Hypoxia (HIF-1alpha) with Genetically Encoded Reporter Genes	18
<i>Speaker: R. Blasberg (USA)</i>		
12:40	Application of Hypoxia Imaging in Radiation Treatment Planning	19
<i>Speaker: N. Wiedemann (Germany)</i>		
13:05	Concluding Remarks	
<i>Speaker: E. Lartigau (France)</i>		

■ 11:15 - 12:40 HALL A7		
Proffered Papers Session: Haematological Malignancies		
<i>Chair: V. Ribrag (France)</i>		
<i>Chair: H. Mellstedt (Sweden)</i>		
11:15	A Phase 3 Study Comparing Melphalan-Prednisone-Lenalidomide (MPR) With High-dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Patients With Multiple Myeloma (MM)	9.200
<i>A. Palumbo, F. Cavallo, F. Di Raimondo, T. Caravita di Toritto, S. Grammatico, P. Corradini, P. Omedè, D. Ben Yehuda, A. Nagler, M. Boccadoro</i>		
11:25	Complete Remissions Observed in a Subset of Paediatric Patients With CD30-expressing Malignant Lymphomas Treated in Clinical Studies of Brentuximab Vedotin (SGN-35)	9.201
<i>M. Fanale, A. Franklin, R. Radhakrishnan, A. Termuhlen, A.K. Gopal, A. Shustov, D.A. Kennedy, E.L. Sievers</i>		
11:35	MRC Myeloma IX Trial-Characterizing the Biologic and Temporal Basis of Efficacy of Long-term Bisphosphonate Treatment in Patients With Multiple Myeloma	9.202
<i>G. Morgan, F.E. Davies, W.M. Gregory, A.J. Szubert, S.E. Bell, M.T. Drayson, R.G. Owen, J.A. Child</i>		
11:45	Question and Answers	
<i>Discussant: V. Ribrag (France)</i>		
11:50	Question and Answers	
12:00	Targeting Pro-survival Bcl-2 Proteins in Haematological Malignancies Driven by Activated Mutant JAK2	9.203
<i>M. Waibel, V.S. Solomon, R. Ralli, E. Vidacs, S.K. Kim, K.M. Banks, R.W. Johnstone</i>		
12:10	Telomerase Inhibition Affects Fludarabine Sensitivity in Primary Chronic Lymphocytic Leukemia Lymphocytes	9.204
<i>M. Shawi, L. Amrein, S.M. Gryaznov, C. Autexier, R. Aloyz</i>		

■ 14:15 - 15:15 HALL C5		
Special Session: Peritoneal Surface Oncology - the Evidence for Locoregional Treatment		
<i>Chair: S. Gonzalez-Moreno (Spain)</i>		
14:15	Peritoneal Carcinomatosis of Colorectal Origin	29
<i>Speaker: F. Quenet (France)</i>		
14:25	Peritoneal Mesothelioma	30
<i>Speaker: M. Deraco (Italy)</i>		
14:35	Pseudomyxoma Peritonei	31
<i>Speaker: S. Gonzalez-Moreno (Spain)</i>		
14:45	Discussion and Roundup	

■ 14:15 - 15:15 HALL A3		
Special Session: The Management of Penile Cancer		
<i>Chair: A. Kiltie (United Kingdom)</i>		
14:15	Update in Penile Cancer - Facts	32
<i>Speaker: C. Meijer (The Netherlands)</i>		
14:25	Surgery in Penile Carcinoma	33
<i>Speaker: E. Solsona (Spain)</i>		
14:35	Penile Cancer Chemotherapy	34
<i>Speaker: M. De Santis (Austria)</i>		
14:45	Discussion and Roundup	

■ 14:15 - 15:15 HALL A6		
Special Session: Immune System and Tumour Response to Radiotherapy		
<i>Chair: To be announced</i>		
14:15	Introduction	
<i>Speaker: To be announced</i>		
14:25	Role of T-Lymphocytes for Tumour Response to Radiotherapy	35
<i>Speaker: S. Formenti (Italy)</i>		
14:35	CD11b Cells Provide Resistance to Radiotherapy	36
<i>Speaker: M.J. Brown (USA)</i>		
14:45	Discussion and Roundup	

■ 14:15 - 15:15 HALL A8		
Special Session: Developments in Surgical Oncology		
<i>Chair: M. Wells (United Kingdom)</i>		
13:15	Improving the Diagnostic Pathway for Men With Prostate Cancer	37
<i>Speaker: M. Emberton (United Kingdom)</i>		
13:25	Robotic Surgery - Opportunities and Issues for Nursing	38
<i>Speaker: S. Martin (United Kingdom)</i>		
13:35	Health-Related Quality of Life as a Prognostic Factor in Patients With Oesophageal Cancer	39
<i>Speaker: P. Lagergren (Sweden)</i>		
13:45	Discussion and Roundup	

■ 14:15 - 15:15 HALL K1		
Special Session: Late Toxicity Treatment of Head and Neck Cancer		
<i>Chair: S. Subramanian (Russian Federation)</i>		
14:15	Biological Insights	40
<i>Speaker: R. Coppes (The Netherlands)</i>		
14:25	Late Functional Outcome in Chemo-Radiation	41
<i>Speaker: H. Langendijk (The Netherlands)</i>		
14:35	Late Functional Outcome Surgery	42
<i>Speaker: A. Dietz (Germany)</i>		
14:45	Discussion and Roundup	

■ 14:15 - 15:15 HALL A9		
Special Session: Issues in Economic Evaluation of New Cancer Therapies		
<i>Chair: D. Parkinson (USA)</i>		
14:15	Cancer Drug Costs - Forecast for Europe - Will the Cost Explode?	43
<i>Speaker: N. Wilking (Sweden)</i>		
14:25	Methodological Issues in Economic Evaluation of New Cancer Therapies	44
<i>Speaker: To be announced</i>		
14:35	Performance-Based Agreement - Theory to Practice- the Current Use in Oncology and Future Trend	45
<i>Speaker: B. Jönsson (Sweden)</i>		
14:45	Discussion and Roundup	

■ 14:15 - 15:15 HALL T1		
Special Session: Too Little or Too Much Surgery for Melanoma		
<i>Chair: A. Testori (Italy)</i>		
14:15	For Sentinel Node Positive Patients - is Complete Lymph Node Resection Still the Standard of Care?	46
<i>Speaker: O. Nieweg (The Netherlands)</i>		
14:30	For Patients With Distant Metastases - Surgery is First Choice of Treatment	47
<i>Speaker: S. Schneebaum (Israel)</i>		
14:45	A Critical View - Selection is the Standard	48
<i>Speaker: A.M.M. Eggermont (France)</i>		
15:00	Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion	

■ 14:15 - 15:15 HALL T2		
Court Room Trial: Patient Information on Trial		
<i>Judge: J. Bowis (United Kingdom)</i>		
<i>Prosecutor: I. Banks (United Kingdom)</i>		
<i>Expert Witness: L. Fallowfield (United Kingdom)</i>		
<i>Expert Witness: K. Radziwill (Poland)</i>		
<i>Expert Witness: E. Bergsten-Nordstrom (Sweden)</i>		
Jury/Audience to Vote Guilty or Not Guilty		

■ 14:15 - 15:15 HALL K2		
Special Session: Adolescent and Young Adult Cancer Patients: Are We Meeting Their Needs?		
<i>Chair: D. Kelly (United Kingdom)</i>		
14:15	Why are Adolescents Diagnosed Later With Cancer?	49
<i>Speaker: F. Gibson (United Kingdom)</i>		
14:25	Life Four to Six Years Beyond Diagnosis	50
<i>Speaker: L. Wettergren (Sweden)</i>		
14:35	Keeping Their World Together - Network-Focused Nursing in Teenager and Young Adult Cancer Care	51
<i>Speaker: P.R. Olsen (Denmark)</i>		
14:45	Discussion and Roundup	

	Abstract N°
17:00	Update CTLA-4 Blockade Using Ipilimumab as First Line and Second Line Therapy for Advanced Melanoma <i>Speaker: J. Wolchok (USA)</i> 91
17:25	Combination Strategies for Ipilimumab <i>Speaker: J.S. Weber (USA)</i> 92
17:50	Concluding Remarks <i>Speaker: L. Zitvogel (France)</i>
■ 16:00 - 18:00 HALL T2	
Advocacy and Ethics Session: The Challenges of Rare Cancers <i>Co-Chair: K. Oliver (United Kingdom)</i>	
16:00	Introduction <i>Co-Chair: R. Schaefer (Germany)</i>
16:05	Four Million Reasons Why we Need to Improve The Rare Cancer Journey <i>Speaker: K. Oliver (United Kingdom)</i>
16:20	Questions and Answers
16:25	Rarity and Research- Challenges for The International Cancer Community <i>Speaker: J.Y. Blay (France)</i>
16:40	Questions and Answers
16:45	Rare Cancer Advocacy Groups and The EMA - Creating a Sustainable Partnership <i>Speaker: K. Westermarck (Sweden)</i>
17:00	Questions and Answers
17:05	The RARECARE Initiative <i>Speaker: P.G. Casali (Italy)</i>
17:20	Questions and Answers
17:25	We Are Here To Help - How Patient Organisations Can Help You Navigate on The Journey <i>Speaker: S. Craine (United Kingdom)</i>
17:40	Concluding Remarks & Discussion
■ 16:00 - 18:00 HALL K2	
Proffered Papers Session: Nursing - Symptoms <i>Chair: F. Charnay-Sonnek (France)</i>	
16:00	Improving Pain Management Due to a Combination of a Pain Consult and Pain Education in Oncology Outpatients 4.173 <i>W.H. Oldenmenger, P.A.E. Sillevius Smitt, C.A.G.M. Van Montfort, P.J. De Raaf, C.C.D. Van der Rijt</i>
16:15	Cancers Related Anxiety Kryptonite - a Randomized Control Trial for the Use of Guided Imagery and Progressive Muscle Relaxation 4.174 <i>A. Charalambous, E. Bozas, I. Androulakis, M. Giannakopoulou</i>
16:30	Managing Breakthrough Cancer Pain New Nursing Guidelines 4.175 <i>Y. Wengström, T. Rustøen, B. Zauratnik, C. Rundström, I. Weisse, J. Geerling, S. Williams, T. Pappa</i>
16:45	A European Survey of Oncology Nurse Breakthrough Cancer Pain Practices 4.176 <i>T. Rustøen, Y. Wengström, B. Zauratnik, C. Rundström, I. Weisse, J. Geerling, S. Williams, T. Pappa</i>
17:00	Handedness and Pain Experience Four Years After Treatment for a Primary Breast Cancer Among Young Women (ELLIPSE 40 Cohort) 4.177 <i>M. Bendiane, D. Rey, A. Bouhnik, C. Cluze, P. Peretti-Watel</i>

	Abstract N°
17:15	Effectiveness of Nurse-led Telephone Follow-up (NLTfU) in Symptom Management of Patients With Colorectal Cancer Receiving Oral Chemotherapy 4.178 <i>O. Craven, C. Hughes, A. Molassiotis</i>
17:30	Chemotherapy and Subjective Cognitive Functioning in Breast Cancer Patients 4.179 <i>M.J.J. Pullens, J. De Vries, L.J.C. Warmerdam, J.A. Roukema</i>
17:45	Using Mobile Phone Technology to Assess Symptoms in Patients Receiving Palliative Care. The Advanced Symptom Management System (ASyMS®-P) 4.180 <i>B. Johnston, R. Maguire, N. Kearney</i>
■ 16:00 - 18:00 HALL A5	
Scientific Symposium: Molecular Cancer Epidemiology - the Next Generation <i>Chair: Z. Herceg (France)</i> <i>Chair: P. Hall (Sweden)</i>	
16:00	Introduction <i>Speaker: Z. Herceg (France)</i>
16:10	Cancer Incidence and Mortality in Europe - GLOBOCAN 2008 93 <i>Speaker: D. Forman (France)</i>
16:35	Genetic Susceptibility - Are We Surfing or Diving Genome? 94 <i>Speaker: P. Pharoah (United Kingdom)</i>
17:00	Are "Environmental Wide Association Studies" (EWAS) the Missing Piece? 95 <i>Speaker: P. Vineis (United Kingdom)</i>
17:25	Human Cancer Epigenetics 96 <i>Speaker: M. Esteller (Spain)</i>
17:50	Concluding Remarks <i>Speaker: P. Hall (Sweden)</i>
■ 16:00 - 18:00 HALL A7	
Scientific Symposium: Role of the Microenvironment in Lymphomas <i>Chair: P. Ghia (Italy)</i> <i>Chair: R. Küppers (Germany)</i>	
16:00	Introduction <i>Speaker: R. Küppers (Germany)</i>
16:10	The Microenvironment in B Cell Malignancies - a New Target for Therapy? 97 <i>Speaker: P. Ghia (Italy)</i>
16:35	The Stromal Cell Niche in Follicular Lymphoma 98 <i>Speaker: K. Tarte (France)</i>
17:00	The Microenvironment in Hodgkin Lymphoma - Pathogenic and Clinical Relevance 99 <i>Speaker: C. Steidl (Canada)</i>
17:25	Impact of the Tumour Microenvironment on Prognosis in Follicular Lymphoma 100 <i>Speaker: D. de Jong (The Netherlands)</i>
17:50	Concluding Remarks <i>Speaker: P. Ghia (Italy)</i>

08:00 - 08:45	HALL A5 Teaching Lecture: DNA Repair as Treatment Target <i>Speaker: T. Helleday (United Kingdom)</i>	
08:00 - 08:45	HALL K11 Teaching Lecture: Current Approaches to Adjuvant Therapy of Melanoma <i>Speaker: S. Aamdal (Norway)</i>	
08:00 - 08:45	HALL T5 Teaching Lecture: Medulloblastoma <i>Speaker: L. Padovani (France)</i>	
08:00 - 08:45	HALL T6 Advocacy and Ethics Session: How Healthcare Professionals and Patient Groups are Using Social Media	
08:00	Introduction <i>Chair: J. Geissler (Germany)</i>	
08:05	The Rare Cancer Online Communities Platform <i>Speaker: D. Costello (France)</i>	
08:15	Social Media Use and Best Practice in European Hospitals <i>Speaker: L. Engelen (The Netherlands)</i>	
08:25	How Patient Advocates and Doctors use Social Media <i>Speaker: K. Apostolidis (Greece)</i>	
09:00 - 10:10	HALL C5 Proffered Papers Session: Lung Cancer-Localised/Local Regional <i>Chair: T. Le Chevalier (France)</i> <i>Chair: to be announced</i>	
09:00	Randomized Phase III Trial of Adjuvant Chemotherapy With Gemcitabine Compared With Oral Tegafur-uracil (UFT) in Resected, Stage IB-IIIa Non-small Cell Lung Cancer (WJTOG 0101) 9.008 <i>T. Mitsudomi, H. Tada, Y. Ichinose, K. Yokoi, N. Katakami, M. Oda, S. Negoro, Y. Chiba, K. Nakagawa, Y. Nakanishi</i>	
09:10	Immunohistochemical Analysis of a Panel of DNA Repair Proteins in NSCLC Predict for Cisplatin Benefit in Resected Squamous-cell Carcinoma but Not in Adenocarcinoma 9.009 <i>K.A. Olausson, W.E. Pierceall, K.M. Spratt, D.T. Weaver, B.E. Ward, J.C. Soria</i>	
09:20	Question and Answers	
09:25	Discussant: G. Scagliotti (Italy)	
09:35	18F-FDG-PET 12 Weeks After Stereotactic Body Radiotherapy for Stage I Non-Small-Cell Lung Cancer Predicts Outcome 9.010 <i>V.R. Bollineni, E.M. Wiegman, J. Pruijm, J.A. Langendijk, J. Widder</i>	
09:45	Multicenter Analysis of High-resolution Computed Tomography and Fluorodeoxyglucose-positron Emission Tomography/computed Tomography to Predict Malignant Grade of Clinical Stage IA Lung Adenocarcinoma 9.011 <i>Y. Miyata, M. Okada, S. Okumura, H. Daisaki, S. Adachi, M. Yoshimura, H. Nakayama</i>	
09:55	Question and Answers	
10:00	Discussant: D. Zips (Germany)	

09:00 - 10:20	HALL A3 Proffered Papers Session: Genitourinary Malignancies - Prostate Cancer <i>Chair: M. Grimm (Germany)</i> <i>Chair: K. Fizazi (France)</i>	
09:00	Final Overall Survival (OS) Analysis of COU-AA-301, a Phase 3 Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pretreated With Docetaxel 7.000 <i>K. Fizazi, H.I. Scher, A. Molina, C.J. Logothetis, R.J. Jones, J.N. Staffurth, J. Li, T. Kheoh, C.M. Haqq, J.S. de Bono</i>	
09:10	Abiraterone Acetate Improves Functional Status in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Post-docetaxel - Results from the COU-AA-301 Phase 3 Study 7.001 <i>S. Harland, J.S. de Bono, C.M. Haqq, J.N. Staffurth, Y. Hao, D. Gagnon, C. Liu, C.N. Sternberg, A. Molina, H.I. Scher</i>	
09:20	Questions and Answers	
10:10	Discussant: M. De Santis (Austria)	
09:35	Time to Disease-related Pain After Sipuleucel-T in Asymptomatic Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) - Results From 3 Randomized Phase III Trials 7.002 <i>E.J. Small, C.S. Higano, P.W. Kantoff, J.B. Whitmore, M.W. Frohlich, D.P. Petrylak</i>	
09:45	Denosumab and Bone Metastasis-free Survival in Men With Castrate-resistant Prostate Cancer - Subgroup Analyses from an International, Double-blind, Randomized, Phase 3 Trial 7.003 <i>S. Oudard, M. Smith, L. Karsh, B. Egerdie, P. Van Veldhuizen, F. Gómez-Veiga, D. Dearnaley, Z. Ye, R. Dansey, C. Goessl</i>	
09:55	Pain Outcomes in a Randomized Phase 3 Clinical Trial of Denosumab Vs Zoledronic Acid (ZA) in Patients With Solid Tumours and Bone Metastases 7.004 <i>L. Fallowfield, R. von Moos, D. Patrick, C.S. Cleeland, D.H. Henry, V. Hirsh, K. Zarogoulidis, W. Ying, Z. Cong, H. Yeh</i>	
10:05	Question and Answers	
10:10	Discussant: J. Bellmunt (Spain)	
09:00 - 10:30	VICTORIA HALL Proffered Papers Session: Personalized Medicine <i>Chair: A.L. Børresen-Dale (Norway)</i> <i>Chair: J.C. Soria (France)</i>	
09:00	Comprehensive Next-Generation Sequencing (NGS) From Formalin-fixed NSCLC, CRC and Melanoma Cancer Tissues Identifies Novel Mutations With Potential Clinical Utility 800 <i>G. Palmer, R. Yelensky, D. Lipson, M. Jarosz, A. Parker, C. Sheehan, S. Downing, J. Curran, M. Cronin, J. Ross</i>	
09:10	High Throughput Molecular Analyses to Select Patients for Targeted Agents 801 <i>M. Arnedos, J. De La Cruz, B. Job, V. Scott, P. Dessen, D. Gentien, S. Roman-Roman, S. Delalogue, V. Lazar, F. Andre</i>	

■ 09:00 - 11:00	HALL A6	
	Scientific Symposium: Impact of Tumour Hypoxia on Heterogeneity in Radiation Response	
	<i>Chair: J. Overgaard (Denmark)</i>	
	<i>Chair: J. Bussink (The Netherlands)</i>	
09:00	Introduction	
	<i>Speaker: J. Bussink (The Netherlands)</i>	
09:10	Cellular Responses to Hypoxia and Consequences for Radiotherapy	111
	<i>Speaker: L. DuBois (The Netherlands)</i>	
09:35	Hypoxia Imaging and Outcome After Radiotherapy - Pre-Clinical Results	112
	<i>Speaker: J. Overgaard (Denmark)</i>	
10:00	Hypoxia Imaging and Outcome After Radiotherapy - Clinical Results	113
	<i>Speaker: P. Dirix (Belgium)</i>	
10:25	Translational Aspects of Hypoxia Modification	114
	<i>Speaker: P. Hoskin (United Kingdom)</i>	
10:50	Concluding Remarks	
	<i>Speaker: J. Overgaard (Denmark)</i>	

■ 09:00 - 11:00	HALL A8	
	Scientific Symposium: Symptom Management	
	<i>Chair: A. Molassiotis (United Kingdom)</i>	
	<i>Chair: A.M. Teller (France)</i>	
09:00	Introduction	
	<i>Speaker: A. Molassiotis (United Kingdom)</i>	
09:10	How Do Women With Breast Cancer Manage Symptoms of Cognitive Impairments While Undergoing Chemotherapy Treatment?	115
	<i>Speaker: F. Munir (United Kingdom)</i>	
09:35	Cough Management in Lung Cancer	116
	<i>Speaker: M. Bennett (United Kingdom)</i>	
10:00	Bone Disease - Osteoporosis	117
	<i>Speaker: K. Leonard (Ireland)</i>	
10:25	Peripheral Neuropathies Associated With Chemotherapy	118
	<i>Speaker: E. Ryd Ausen (Sweden)</i>	
10:50	Concluding Remarks	
	<i>Speaker: A.M. Teller (France)</i>	

■ 09:00 - 11:00	HALL K1	
	Scientific Symposium: Tumour Microenvironment	
	<i>Chair: M.J. Bissell (USA)</i>	
	<i>Chair: J.W. Pollard (USA)</i>	
09:00	Introduction	
	<i>Speaker: J.W. Pollard (USA)</i>	
09:10	Why Do We Get So Few Cancers?!	119
	<i>Speaker: M.J. Bissell (USA)</i>	
09:35	Monocyte and Macrophage Diversity Promotes Tumour Progression and Metastasis	120
	<i>Speaker: J.W. Pollard (USA)</i>	
10:00	Anticancer Approaches Based on Tumour Hypoxia and Metabolism	121
	<i>Speaker: J. Pouyssegur (France)</i>	
10:25	Tumour - Stroma Interactions in Breast Cancer Metastasis	122
	<i>Speaker: C. Isacke (United Kingdom)</i>	
10:50	Concluding Remarks	
	<i>Speaker: M.J. Bissell (USA)</i>	

■ 09:00 - 11:00	HALL A9	
	Scientific Symposium: The Application of Pharmacometrics in Oncology	
	<i>Chair: P. Hartvig (Denmark)</i>	
	<i>Chair: A. Astier (France)</i>	
09:00	Introduction	
	<i>Speaker: P. Hartvig (Denmark)</i>	
09:10	Application of Population PK-PD Methods in Oncology	123
	<i>Speaker: E. Chatelut (France)</i>	
09:35	Considerations in PK-PD of Antibodies	124
	<i>Speaker: C. Kloft (Germany)</i>	
10:00	Pharmacometrics to Improve Treatment of Cancer in Children	125
	<i>Speaker: A. Huitema (The Netherlands)</i>	
10:25	Optimising Phase I Trials With Modelling and Simulation Using Pharmacometrics	126
	<i>Speaker: I. Trocóniz (Spain)</i>	
10:50	Concluding Remarks	
	<i>Speaker: A. Astier (France)</i>	

■ 09:00 - 11:00	HALL T1	
	Scientific Symposium: Melanoma Therapy - Realising the Potential in Targeted Therapy	
	<i>Chair: R. Marais (United Kingdom)</i>	
	<i>Chair: C. Robert (France)</i>	
09:00	Introduction	
	<i>Speaker: C. Robert (France)</i>	
09:10	Basics of BRAF	127
	<i>Speaker: R. Marais (United Kingdom)</i>	
09:35	Melanoma Therapy - Realising the Potential in Targeted Therapy	128
	<i>Speaker: K. Flaherty (USA)</i>	
10:00	Combining TKI's in Melanoma: Which Rationale, How and When	129
	<i>Speaker: A. Ribas (USA)</i>	
10:25	TKI's, BRAF Inhibitors and the Problem of New Toxicities such as Keratoacanthoma and Induction of Invasive SCC	130
	<i>Speaker: C. Robert (France)</i>	
10:50	Concluding Remarks	
	<i>Speaker: R. Marais (United Kingdom)</i>	

■ 09:00 - 11:00	HALL T2	
	Advocacy and Ethics Session: Cancer at Any Age - Ethics and Challenges	
09:00	Introduction	
	<i>Co-Chair: T. Hudson (Ireland)</i>	
	<i>Co-Chair: L. Jost (Switzerland)</i>	
09:05	Ethical Learnings from Paediatric Cancer Research	
	<i>Speaker: D. Walker (United Kingdom)</i>	
09:20	Questions and Answers	
09:25	Ethical Dilemmas in the Management of Teenage Cancer Patients	
	<i>Speaker: L. Soanes (United Kingdom)</i>	
09:40	Questions and Answers	
09:45	To Enrol or Not To Enrol - Ethical Considerations for Clinical Trial Participation	
	<i>Speaker: N. Stingelin (Switzerland)</i>	
10:00	Questions and Answers	

10:05	Too Old to Be Treated? <i>Speaker: M. Aapro (Switzerland)</i>	
10:20	Questions and Answers	
10:25	Palliative Care: More Than Just End of Life Treatment <i>Speaker: N.I. Cherny (Israel)</i>	
10:40	Concluding Remarks & Discussion	

■ 09:00 - 11:00 HALL A5

Proffered Papers Session: Nursing - Service Delivery and Care Initiatives

Chair: D. Papageorgiou (Greece)

09:00	Crossing Boundaries: the Role of the Advanced Nurse Practitioner in an Integrated Specialist Palliative Care Service in Scotland <i>C. Kennedy, C. Gray, P. Black</i>	4.150
09:15	A Randomised Crossover Trial to Determine Safety, Quality of Life and Economic Consequences of Home - Based Chemotherapy <i>B. Christiansen, A. Rishøj, B.V. Jensen, F.O. Larsen, D. Nielsen</i>	4.151
09:30	Improving Breast and Lung Cancer Services in Hospital Using Experience Based Co-design (EBCD) <i>T. Wiseman, V. Tsianakas, J. Maben, G. Robert, A. Richardson</i>	4.152
09:45	Developing and Testing a Novel, Evidence-based and User-tested Toolkit for Assessing and Improving Teamworking in Multidisciplinary Cancer Teams <i>C. Taylor, K.B. Brown, N. Seudalis, J.S.A. Green</i>	4.153
10:00	Patients' Perceptions of Caring When Receiving Home or Hospital Care During the Acute Posttransplant Phase After Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) <i>K. Bergkvist, B.M. Svahn, E. Martell, J. Larsen</i>	4.154
10:15	How Can We Measure Nursing Sensitive Outcomes in an Oncology Nursing Minimum Data Set (ONMDS)? <i>A. Milani, S. Mauri, C. Beltrami, V. Brunelli, G. Cherchi, M. Clerici, C. Grossi, A. Gandini, A. Brunoldi, G. Magon</i>	4.155
10:30	The Development of a Dignity Care Pathway (DCP) for Use by Community Nurses With People Receiving End of Life Care at Home <i>B. Johnston, U. Ostlund, H. Brown, H. Chochinov</i>	4.156
10:45	Developing and Feasibility Testing of Nurse Sensitive Outcome Measures for Ambulatory Cancer Chemotherapy <i>J. Armes, P. Griffiths, A. Richardson, R. Wagland, J. Finnegan-John, J. Corner</i>	4.157

■ 09:00 - 11:00 HALL A7

Scientific Symposium: Molecular Genetics in Lymphoma - Current Knowledge and New Insights From High-Throughput Technologies

Chair: T. Zenz (Germany)

Chair: V. Ribrag (France)

09:00	Introduction <i>Speaker: T. Zenz (Germany)</i>	
09:10	Chronic Lymphocytic Leukaemia (CLL) <i>Speaker: T. Zenz (Germany)</i>	131
09:35	Mantle Cell Lymphoma (MCL) <i>Speaker: A. Wiestner (USA)</i>	132
10:00	Diffuse Large Cell Lymphoma (DLCL) <i>Speaker: A. Rosenwald (Germany)</i>	133

10:25	A Molecular Portrait of Follicular Lymphoma <i>Speaker: J. Fitzgibbon (United Kingdom)</i>	134
10:50	Concluding Remarks <i>Speaker: V. Ribrag (France)</i>	

■ 09:00 - 11:00 HALL K11

Scientific Symposium: Multidisciplinary Quality Assurance

Chair: M. Baumann (Germany)

09:00	Introduction <i>Speaker: M. Baumann (Germany)</i>	
09:25	Quality Assurance of Oral Compliance <i>Speaker: K. Meier (Germany)</i>	135
09:50	Quality Assurance Through Outcome Registration in Colorectal Cancer - An ECCO Initiative for Europe <i>Speaker: C.J.H. van de Velde (The Netherlands)</i>	136
10:15	Quality Assurance of Radiotherapy <i>Speaker: J. Bernier (Switzerland)</i>	137
10:40	Concluding Remarks <i>Speaker: M. Baumann (Germany)</i>	

■ 09:00 - 11:00 HALL T6

Scientific Symposium: Novel Oncoproteomic Technology

Chair: R. Aebersold (USA)

Chair: G. Pestlin (Germany)

09:00	Introduction <i>Speaker: G. Pestlin (Germany)</i>	
09:10	Proteomics and Personalised Medicine- Label-free Mass Spectrometry <i>Speaker: C. Jimenez (The Netherlands)</i>	138
09:30	High Resolution Mass Spectrometry-Based Proteomics for Metabolism and Cancer Research <i>Speaker: T. Walther (USA)</i>	139
09:50	Clinical Proteomics in the Early Detection of Breast Cancer <i>Speaker: J. Celis (Denmark)</i>	140
10:10	Protein Kinase Activity and Therapy Response <i>Speaker: K. Røe (Norway)</i>	141
10:30	Cancer Protein Biomarkers <i>Speaker: R. Aebersold (USA)</i>	142
10:50	Concluding Remarks <i>Speaker: R. Aebersold (USA)</i>	

■ 09:00 - 11:00 HALL A1

Proffered Papers Session: Breast Cancer - Advanced Disease

Chair: F. Andre (France)

Chair: J. Bergh (Sweden)

09:00	Long-term Outcome of HER2-positive (HER2+) Metastatic Breast Cancer (MBC) Patients (pts) Achieving Durable Complete Remission (DCR) After Trastuzumab (T)-containing Chemotherapy (CT) <i>G. Gullo, M. Zuradelli, F. Kelleher, F. Sclafani, N. O' Donovan, T. Lyons, G. Masci, A. Santoro, J. Crown</i>	5.000
-------	---	-------

■	13:15 - 14:15	HALL A6 Debate: This House Believes That Patients With HPV+ve Tumours Should Be Managed Differently From Those With HPV-ve Tumours <i>Moderator: J.B. Vermorken (Belgium)</i>	
	13:20	Patients With HPV+ve Tumours Should Be Managed Differently From Those With HPV-ve Tumours <i>Speaker in favour: M.L. Gillison (USA)</i>	
	13:35	Patients With HPV+ve Tumours Should NOT Be Managed Differently From Those With HPV-ve Tumours <i>Speaker against: H. Mehanna (United Kingdom)</i>	
	13:50	Patients With HPV+ve Tumours Should Be Managed Differently From Those With HPV-ve Tumours <i>Seconder in favour: J.-P. Klussmann (Germany)</i>	
	13:57	Patients With HPV+ve Tumours Should NOT Be Managed Differently From Those With HPV-ve Tumours <i>Seconder against: L. Licitra (Italy)</i>	
	16:04	Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion	
■	13:15 - 14:15	HALL A8 Special Session: Fertility Concerns <i>Chair: J. Denton (United Kingdom)</i>	
	13:15	Frozen Hope - Fertility Preservation for Women With Cancer <i>Speaker: J. Denton (United Kingdom)</i>	150
	13:25	Male Infertility and Cancer <i>Speaker: A. Pacey (United Kingdom)</i>	151
	13:35	Same Sex Couples Fertility Issues <i>Speaker: L. Moegelin (Sweden)</i>	152
	13:45	Discussion and Roundup	
■	13:15 - 14:15	HALL K1 Special Session: Esophageal Cancer - Ways to Improve Outcome <i>Chair: T. Lehnert (Germany)</i>	
	13:15	How Radical Should Surgery Be? <i>Speaker: C. Mariette (France)</i>	153
	13:25	Neoadjuvant Treatment - Better than Surgery Alone? <i>Speaker: T. Lehnert (Germany)</i>	154
	13:35	Will Centralization Improve Outcome? <i>Speaker: R.C. Mason (United Kingdom)</i>	155
	13:45	Discussion and Roundup	
■	13:15 - 14:15	HALL A9 Special Session: Cross-Over in Trials <i>Chair: I.F. Tannock (Canada)</i>	
	13:15	Early Approval Versus Late Approval <i>Speaker: F. Pignatti (United Kingdom)</i>	156
	13:25	Cross-over in Oncology Clinical Trials - Statistical Issues <i>Speaker: D. Sargent (USA)</i>	157
	13:35	Cross-over in Clinical Trials - The Clinician's Perspective <i>Speaker: I.F. Tannock (Canada)</i>	158
	13:45	Discussion and Roundup	

■	13:15 - 14:15	HALL T1 Special Session: Stem Cells <i>Chair: R. Toftgård (Sweden)</i>	
	13:15	Stem Cells and Skin Cancer <i>Speaker: R. Toftgård (Sweden)</i>	159
	13:25	Haematopoietic Stem Cells <i>Speaker: P.G. Pelicci (Italy)</i>	160
	13:25	Stem Cells <i>Speaker: S. Niclou (Luxembourg)</i>	161
	13:45	Discussion and Roundup	
■	13:15 - 14:15	HALL T2 Advocacy and Ethics Session: Cancer and the Internet	
	13:15	Introduction <i>Chair: J. Geissler (Germany)</i>	
	13:20	Eurocancercoms: Cancer Superportal <i>Speaker: R. Sullivan (United Kingdom)</i>	
	13:30	Serving Patient Communities Through Social Media <i>Speaker: D. Costello (France)</i>	
	13:40	Running Sustainable Online Communities <i>Speaker: G. Frydman (USA)</i>	
	13:50	How University Hospitals and Cancer Patients Can Collaborate Online <i>Speaker: L. Engelen (The Netherlands)</i>	
	14:00	Concluding Remarks & Discussion	
■	13:15 - 14:15	HALL K2 Special Session: Endpoints in Clinical Trials <i>Chair: R. Grant (United Kingdom)</i>	
	13:15	MR-response Criteria in Neurooncology <i>Speaker: M. Bendszus (Germany)</i>	162
	13:25	Endpoints for Phase II Trials <i>Speaker: S. Chang (USA)</i>	163
	13:35	Endpoints for Phase III Trials <i>Speaker: M.J. van den Bent (The Netherlands)</i>	164
	13:45	Discussion and Roundup	
■	13:15 - 14:15	HALL A5 Special Session: Calories and Cancer <i>Chair: A. Gescher (United Kingdom)</i>	
	13:15	Body Mass Index and Cancer Incidence <i>Speaker: A. Renehan (United Kingdom)</i>	165
	13:25	Starvation and Differential Stress Resistance in Cancer Treatment <i>Speaker: V.D. Longo (USA)</i>	166
	13:35	Energy Balance Including Physical Activity Influence Breast and Colon Carcinogenesis - Results From Recent Studies <i>Speaker: I. Thune (Norway)</i>	167
	13:45	Discussion and Roundup	
■	13:15 - 14:15	HALL A7 Special Session: Tips and Tricks to be the Best <i>Chair: I.R.H.M. Konings (The Netherlands)</i>	
	13:15	Middle Face Microvascular Reconstructions Based on Cordeiro Classification <i>Speaker: A. Maciejewski (Poland)</i>	168

- 14:45 - 16:45 **HALL A1**
Educational Symposium: Optimal Treatment for Advanced Ovarian Cancer
Chair: I.B. Vergote (Belgium)
- 14:45 **Primary Surgery or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery in Advanced Ovarian Cancer**
Speaker: I.B. Vergote (Belgium)
- 15:15 **First Line Therapy: Have We Made Any Improvement?**
Speaker: M. Bookman (USA)
- 15:45 **Clinical Trials and Decision-making Strategies for Optimal Treatment of Relapsed Ovarian Cancer**
Speaker: J. Ledermann (United Kingdom)
- 16:15 **The Role of Targeted Therapy in Ovarian Cancer**
Speaker: S.B. Kaye (United Kingdom)
-
- 14:45 - 16:45 **VICTORIA HALL**
Scientific Symposium: Tailored Chemotherapy in Colon Cancer
Chair: E. Van Cutsem (Belgium)
Chair: P. Rougier (France)
- 14:45 **Introduction**
Speaker: E. Van Cutsem (Belgium)
- 14:55 **The Genomic and Stem Cell Perspective** 177
Speaker: I. Tomlinson (United Kingdom)
- 15:15 **The Role of Microsatellite Instability in the Era of Personalized Medicine** 178
Speaker: E. Vilar (USA)
- 15:35 **Optimal Approach on the KRAS Wild Type** 179
Speaker: P. Rougier (France)
- 15:55 **Optimal Approach of the KRAS Mutant** 180
Speaker: E. Van Cutsem (Belgium)
- 16:15 **The Angiogenesis Inhibition** 181
Speaker: M. Dicato (Luxembourg)
- 16:35 **Concluding Remarks**
Speaker: P. Rougier (France)
-
- 14:45 - 16:45 **HALL C5**
Scientific Symposium: Joint ECCO and ASCO Scientific Symposium on Improving the Quality of Delivered Cancer Care by Tools and Guidelines
Chair: C.J.H. van de Velde (The Netherlands)
Chair: M. Link (USA)
- 14:45 **Introduction**
Speaker: C.J.H. van de Velde (The Netherlands)
- 14:55 **Paediatrics as Model of Centralising Treatment of Rare Cancers** 182
Speaker: R. Pieters (The Netherlands)
- 15:20 **QOPI Project** 183
Speaker: D. Blayney (USA)
- 15:45 **Electronic Health Records and Other Health Information Technology and Their Ability to Measure and Improve Cancer Care** 184
Speaker: L. Shulman (USA)
- 16:10 **Eurocancoms Project - Multidisciplinary Guidelines Where Are We?** 185
Speaker: D. Schrijvers (Belgium)
- 16:35 **Concluding Remarks**
Speaker: M. Link (USA)

- 14:45 - 16:45 **HALL K1**
Educational Symposium: Screening for Cancer: Sense and Sensibilities
Chair: H.J. de Koning (The Netherlands)
- 14:45 **Breast Cancer Screening**
Speaker: P. Autier (France)
- 15:15 **Lung Cancer Screening**
Speaker: H.J. de Koning (The Netherlands)
- 15:45 **Screening for Colorectal Cancer: Sense and Sensibilities**
Speaker: G. Vanhal (Belgium)
- 16:15 **Screening for Prostate Cancer**
Speaker: F.H. Schroeder (The Netherlands)
-
- 14:45 - 16:45 **HALL T1**
Scientific Symposium: Improved Pain Control Through a Collaborative Approach Between Oncology, Pain and Palliative Care Specialists
Chair: S. Kaasa (Norway)
Chair: D. Büche (Switzerland)
- 14:45 **Introduction**
Speaker: D. Büche (Switzerland)
- 14:55 **How to Improve Cancer Pain Control Through European Guidelines for Opioid Treatment and Cancer Pain Diagnosis** 189
Speaker: S. Kaasa (Norway)
- 15:15 **Chemotherapy Including Modern Targeted Therapies to Prevent and to Treat Cancer Pain** 190
Speaker: N.I. Cherny (Israel)
- 15:35 **What Is the Place for an Effect of Surgery to Prevent and/or to Treat Cancer Pain** 191
Speaker: B. Axelsson (Sweden)
- 15:55 **What Is the Place and Effect of Radiotherapy and What Is the Optimal Schedule for Cancer Pain** 192
Speaker: P. Hoskin (United Kingdom)
- 16:15 **A Future Research Agenda to Improve Pain Control Through Collaborative Efforts** 193
Speaker: D. Büche (Switzerland)
- 16:35 **Concluding Remarks**
Speaker: S. Kaasa (Norway)
-
- 14:45 - 16:45 **HALL T2**
Advocacy and Ethics Session: Cancer Research - Ethics and Challenges
- 14:45 **Introduction**
Co-Chair: I. Kössler (Sweden)
Co-Chair: N. Wilking (Sweden)
- 14:50 **Clinical Trials - Are Patients 'Lost in Translation'?**
Speaker: P. Garcia-Prieto (Belgium)
- 15:05 **Questions and Answers**
- 15:10 **Ethics in Cancer Biobanking**
Speaker: K. Zatloukal (Austria)
- 15:25 **Questions and Answers**
- 15:30 **Patient Advocates and Ethical Review Boards**
Speaker: P. Knüpfer (Germany)

15:45	Questions and Answers	
15:50	Should ALL Trial Results - Good and Bad - Be Published and Made Publicly Available?	
	<i>Speaker: U. Ringborg (Sweden)</i>	
16:05	Questions and Answers	
16:10	Conventional Medicine and CAM - a Happy Partnership?	
	<i>Speaker: H. Jernström (Sweden)</i>	
16:25	Concluding Remarks & Discussion	

■ 14:45 - 16:45	HALL K2	
	Scientific Symposium: The Role of Medical Technology in Building a Sustainable Cancer Care	
	<i>Chair: M. Baumann (Germany)</i>	
14:45	Introduction	
	<i>Speaker: M. Baumann (Germany)</i>	
14:55	How Medical Technologies and Pharmaceutical Industry Can Work Together	194
	<i>Speaker: F. Ginty (United Kingdom)</i>	
15:20	Recent and Future Advances in Cancer Imaging	195
	<i>Speaker: S. Schubert (USA)</i>	
15:45	IT Enabled Clinical Decision Support and Integration of Cancer Care-Role of EMR and Cancer Registries	196
	<i>Speaker: J. Goldwein (Sweden)</i>	
16:10	Molecular Diagnostics Role in Personalised Cancer Care	197
	<i>Speaker: K. Bloom (United Kingdom)</i>	
16:15	The Future of Radiation Therapy in Comprehensive Cancer Care	198
	<i>Speaker: S. Johansson (Sweden)</i>	
16:40	Concluding Remarks	
	<i>Speaker: M. Baumann (Germany)</i>	

■ 14:45 - 16:45	HALL A7	
	Scientific Symposium: Brain Tumours in Children and Adolescents	
	<i>Chair: D. Walker (United Kingdom)</i>	
	<i>Chair: I. Slauc (Austria)</i>	
14:45	Introduction	
	<i>Speaker: D. Walker (United Kingdom)</i>	
15:20	Are Adult and Paediatric High Grade Gliomas the Same - Insight From Biology and Molecular Pathology	199
	<i>Speaker: J. Grill (France)</i>	
15:20	The EU Research Strategy for High Grade Glioma in Children and Adolescents - Can We Extrapolate From Adult Data?	200
	<i>Speaker: D. Hargrave (United Kingdom)</i>	
15:45	Molecular Characterization of Medulloblastoma - the Route Towards Personalized Care	201
	<i>Speaker: T. Pietsch (Germany)</i>	
16:10	Functional Imaging in Adult and Paediatric Brain Tumours	202
	<i>Speaker: A.C. Peet (United Kingdom)</i>	
16:35	Concluding Remarks	
	<i>Speaker: I. Slauc (Austria)</i>	

■ 14:45 - 16:45	HALL T6	
	Special Session: MIRACLE Workshop: Novel Technologies For The Isolation And Analysis of Circulating Tumour Cells	
	<i>Chair: L. Lagae (Belgium)</i>	
14:45	Enumeration and Characterization of Circulating Tumour Cells	203
	<i>Speaker: L. Terstappen (The Netherlands)</i>	
15:10	Microchip-based CTC isolation	204
	<i>Speaker: P. Gascoyne (USA)</i>	
15:35	Biomechanics Based Microfluidic Biochip for the Label-free Isolation and Retrieval of Circulating Tumour Cells	205
	<i>Speaker: C.T. Lim (Singapore)</i>	
16:00	MIRACLE Project	
	<i>Speaker: L. Lagae (Belgium)</i>	

■ 15:00 - 16:00	HALL A3	
	Special Session: Novel Targeted Therapies for Metastatic Non-Small Cell Lung Cancer	
	<i>Chair: R. Dziadziszko (Poland)</i>	
15:00	ALK Inhibitors in Lung Cancer	186
	<i>Speaker: D.R. Camidge (USA)</i>	
15:10	IGF1R Inhibitors	187
	<i>Speaker: L. Paz Ares (Spain)</i>	
15:20	Novel Molecular Targeted Agents in NSCLC (Beyond EGFR, ALK and IGF1R)	188
	<i>Speaker: J.C. Soria (France)</i>	
15:30	Discussion and Roundup	

■ 15:00 - 16:00	HALL A8	
	Debate: This House Believes That Surgery is the Mainstay for the Treatment of PT2 Bladder Cancer	
	<i>Moderator: J. Bellmunt (Spain)</i>	
15:05	Surgery is the Mainstay for the Treatment of PT2 Bladder Cancer	
	<i>Speaker in favour: M. Wirth (Germany)</i>	
15:20	Surgery is NOT the Mainstay for the Treatment of PT2 Bladder Cancer	
	<i>Speaker against: A.L. Zietman (USA)</i>	
15:35	Surgery is the Mainstay for the Treatment of PT2 Bladder Cancer	
	<i>Seconder in favour: A.R. Zlotta (Canada)</i>	
15:42	Surgery is NOT the Mainstay for the Treatment of PT2 Bladder Cancer	
	<i>Seconder against: A. Kiltie (United Kingdom)</i>	
15:49	Questions and Answers Including Audience and Final Vote to See If Audience Have Changed Their Opinion	

■ 15:00 - 16:00	HALL A9	
	Debate: This House Believes That Prospective Randomised Trials Should Be Stopped If At Interim Analysis a Sufficient Positive Effect Can Be Detected	
	<i>Moderator: D. Lacombe (Belgium)</i>	
15:05	Prospective Randomised Trials Should Be Stopped If At Interim Analysis a Sufficient Positive Effect Can Be Detected	
	<i>Speaker in favour: D. Finkelstein (USA)</i>	
15:20	Prospective Randomised Trials Should NOT Be Stopped If At Interim Analysis a Sufficient Positive Effect Can Be Detected	
	<i>Speaker against: J. Bogaerts (Belgium)</i>	

■ 16:45 - 18:15 **HALL K11**
Society Session: European Society of Oncology Pharmacy (ESOP): Oral Chemotherapy: From Absorption to Adherence: Is The Patient Being Treated?
Chair: P. Hartvig (Denmark)
Absorption Issues With Oral Drugs 241
Speaker: W. Weitschies (Germany)
Adherence Issues With Oral Chemotherapy 242
Speaker: M. Daouphars (France)
Pharmacist Role 243
Speaker: K. Meier (Germany)

■ 16:45 - 18:15 **HALL T5**
Society Session: The European Society for Paediatric Oncology (SIOP Europe)
General Introduction
Chair: R. Ladenstein (Austria)
Introduction Dr Patte
Co-Chair: G. Vassal (France)
Introduction Prof. Reiter
Co-Chair: M. Schrappe (Germany)
 16:45 **Award Lecturer I**
Award Lecturer: C. Patte (France)
 17:15 **Award Lecturer II**
Award Lecturer: A. Reiter (Germany)
 17:45 **To be confirmed**
Speaker: To be announced

■ 16:45 - 18:15 **HALL T6**
Society Session: European School of Oncology (ESO) - Prostate Cancer Units
Chair: A. Costa (Italy)
Chair: L. Denis (Belgium)
Welcome
Speaker: A. Costa (Italy)
 16:55 **Prostate Cancer Patients - What Do They Really Need?** 244
Speaker: L. Denis (Belgium)
 17:10 **The Concept of Prostate Cancer Units** 245
Speaker: R. Valdagni (Italy)
 17:50 **Panel Discussion**
L. Bellardita, L. Denis, C. Parker, C. Sternberg, B. Tombal

■ 17:15 - 18:15 **HALL T2**
Special Session: Not Just Research Subjects, but Research Allies - Patient Involvement in The Design, Conduct and Dissemination of Clinical Trials
Moderator: R. Sullivan (United Kingdom)
Panel: G. Cruickshank (United Kingdom)
I. Klingmann (Belgium)
A. Fehervary (Italy)
R. Wilson (United Kingdom)
D. Lacombe (Belgium)

■ 09:30 - 12:00 **HALL C (EXHIBITION HALL)**
Poster Session: Head and Neck Cancer

001 **Outcome of Radiotherapy Alone for Locoregionally Advanced Head and Neck Cancer Patients Unfit for Chemotherapy** 8.508***
S. Huang, L. Cheng, W. Xu, J. Waldron, A. Bayley, J. Kim, L. Dawson, A. Hope, J. Cho, B. O'Sullivan

002 **Comorbidity in Radiotherapy-treated Head and Neck Cancer - the Impact of Individual Comorbidities on Survival** 8.509***
C.R. Boeje, J. Overgaard

003 **Screening Examination for Superficial Head and Neck Cancer in Patients Who Underwent Endoscopic Resection for Squamous Cell Carcinoma of the Esophagus - a Recent Outcome** 8.510***
Y. Shimizu, T. Yoshida, M. Kato, N. Oridate, M. Asaka

004 **Phase I Trial of Albumin-bound Paclitaxel (A), Cisplatin (P) and 5-Fluorouracil (F) as Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy (CRT) With Carboplatin (Cb) in Patients (pts) With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)** 8.511***
I. Diaz-Padilla, J. Waldron, A. Hope, E.X. Chen, K. Chan, J. Kim, B. O'Sullivan, A.R. Abdul Razak, S.F. Chin, L.L. Siu

005 **A Three-Arm Randomized Trial Comparing Neo-Adjuvant or Concurrent Weekly Cisplatin to Radiotherapy Alone for Locally Advanced Head and Neck Squamous Cell Cancer (HNSCC)** 8.512***
S. Kumar, N.R. Datta, Y.S. Nagar, P. Lal, S. Singh, N. Rastogi, R. Bajpai, A. Srivastava

007 **Should Elderly Patients With Locally Advanced Oropharyngeal Squamous Cell Carcinoma Be Offered the Same Curative Treatment Options as Younger Patients?** 8.514***
K. Geropantas, S.W. Lo, Z. Tasigiannopoulos, I. Worthington, W.M.C. Martin, T.W. Roques

006 **A Phase II Study of Neoadjuvant Bio-chemotherapy With Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Head and Neck Cancer - Representative of Head and Neck Cancer Study Group of Taiwan Cooperative Oncology Group** 8.513***
K.Y. Chang, C.J. Yen, C.Y. Hsieh, H.H. Tsou, C.F. Chiu, C.C. Chen, C.J. Tsao, K.Y. Tsai, S.T. Tsai, J.Y. Chang

008 **A Dose Escalation Study With Intensity Modulated Radiation Therapy (IMRT) in Moderately Advanced (T2No, T2N1, T3No) Squamous Cell Carcinomas (SCC) of the Oropharynx, Larynx and Hypopharynx Using a Simultaneous Integrated Boost (SIB) Approach** 8.515***
M. Leclerc, P. Maingon, M. Hamoir, F. Bonnetain, G. Calais, S. Nuyts, A. Serre, V. Grégoire

009 **Predictive Factors of Critical Weight Loss During Radiotherapy of Head and Neck Cancer** 8.516***
G.B. Petersen, J.R. Andersen, J. Johansen